Gene Name |
chemokine (C-X-C motif) receptor 4 |
dipeptidyl-peptidase 4 |
Image |
|
|
Gene Ontology Annotations |
Cellular Component |
|
|
Molecular Function |
|
|
Biological Process |
|
|
Pathways |
|
|
Drugs |
|
- Atorvastatin
- Sitagliptin
- 2-Amino-3-Methyl-1-Pyrrolidin-1-Yl-Butan-1-One
- 5-(Aminomethyl)-6-(2,4-Dichlorophenyl)-2-(3,5-Dimethoxyphenyl)Pyrimidin-4-Amine
- Alpha-D-Mannose
- (2s)-Pyrrolidin-2-Ylmethylamine
- Iodo-Phenylalanine
- Diisopropylphosphono Group
- 1-(1-phenylcyclopentyl)methylamine
- (S)-2-[(R)-3-amino-4-(2-fluorophenyl)butyryl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
- Vildagliptin
- Alogliptin
- Saxagliptin
- (1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-PROP-1-YN-1-YLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE
- N-(TRANS-4-{(1S,2S)-2-AMINO-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-1-METHYL-3-OXOPROPYL}CYCLOHEXYL)-N-METHYLACETAMIDE
- (2S,3S)-4-cyclopropyl-3-{(3R,5R)-3-[2-fluoro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazolidin-5-yl}-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
- (2S,3S)-3-{3-[2-chloro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-cyclopentylidene-4-cyclopropyl-1-fluorobutan-2-amine
- (3R,4R)-4-(pyrrolidin-1-ylcarbonyl)-1-(quinoxalin-2-ylcarbonyl)pyrrolidin-3-amine
- (7R,8R)-8-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydroimidazo[1,2-a:4,5-c\']dipyridin-7-amine
- (2S,3S)-3-{3-[4-(METHYLSULFONYL)PHENYL]-1,2,4-OXADIAZOL-5-YL}-1-OXO-1-PYRROLIDIN-1-YLBUTAN-2-AMINE
- (1S,2R,5S)-5-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-2-(2,4,5-TRIFLUOROPHENYL)CYCLOHEXANAMINE
- (2R)-4-[(8R)-8-METHYL-2-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[1,5-A]PYRAZIN-7(8H)-YL]-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE
- (2S,3S)-3-AMINO-4-(3,3-DIFLUOROPYRROLIDIN-1-YL)-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-6-YLCYCLOHEXYL)BUTANAMIDE
- (2S,3S)-3-AMINO-4-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-5-YLCYCLOHEXYL)BUTANAMIDE
- (3R)-4-[(3R)-3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL]-3-METHYL-1,4-DIAZEPAN-2-ONE
- 4\'-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]biphenyl-3-carboxamide
- (2R,3R)-7-(methylsulfonyl)-3-(2,4,5-trifluorophenyl)-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-2-amine
- 7-(aminomethyl)-6-(2-chlorophenyl)-1-methyl-1H-benzimidazole-5-carbonitrile
- (3R)-4-[(3R)-3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL]-3-(2,2,2-TRIFLUOROETHYL)-1,4-DIAZEPAN-2-ONE
- METHYL 4-{[({[(2R,5S)-5-{[(2S)-2-(AMINOMETHYL)PYRROLIDIN-1-YL]CARBONYL}PYRROLIDIN-2-YL]METHYL}AMINO)CARBONYL]AMINO}BENZOATE
- (1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-ETHYNYLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE
- 1-biphenyl-2-ylmethanamine
- (1S,3S,5S)-2-{(2S)-2-amino-2-[(1R,3S,5R,7S)-3-hydroxytricyclo[3.3.1.1~3,7~]dec-1-yl]acetyl}-2-azabicyclo[3.1.0]hexane-3-carbonitrile
- (2R)-N-[(2R)-2-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-N-[(5R)-5-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-L-PROLINAMIDE
- (3R,4S)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE
- N-({(2S)-1-[(3R)-3-AMINO-4-(2-FLUOROPHENYL)BUTANOYL]PYRROLIDIN-2-YL}METHYL)BENZAMIDE
- (4R,5R)-5-AMINO-1-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-2-ONE
- (3R,4S)-1-(3,4-DIMETHOXYPHENYL)-3-(3-METHYLPHENYL)PIPERIDIN-4-AMINE
- 1-[2-(S)-AMINO-3-BIPHENYL-4-YL-PROPIONYL]-PYRROLIDINE-2-(S)-CARBONITRILE
- (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE
- (2R)-4-(2-BENZOYL-1,2-DIAZEPAN-1-YL)-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE
- (3R,4R)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-3-AMINE
- 2-(4-{(3S,5S)-5-[(3,3-difluoropyrrolidin-1-yl)carbonyl]pyrrolidin-3-yl}piperazin-1-yl)pyrimidine
- N-({(2S)-1-[(3R)-3-amino-4-(3-chlorophenyl)butanoyl]pyrrolidin-2-yl}methyl)-3-(methylsulfonyl)benzamide
- (3R,4S)-1-[6-(6-METHOXYPYRIDIN-3-YL)PYRIMIDIN-4-YL]-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE
- 6-(4-{(1S,2S)-2-AMINO-1-[(DIMETHYLAMINO)CARBONYL]-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-3-OXOPROPYL}PHENYL)-1H-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-4-IUM
- 7-BENZYL-1,3-DIMETHYL-8-PIPERAZIN-1-YL-3,7-DIHYDRO-PURINE-2,6-DIONE
- 2-({2-[(3R)-3-AMINOPIPERIDIN-1-YL]-4-OXOQUINAZOLIN-3(4H)-YL}METHYL)BENZONITRILE
- 4-[(3R)-3-{[2-(4-FLUOROPHENYL)-2-OXOETHYL]AMINO}BUTYL]BENZAMIDE
- 2-({8-[(3R)-3-AMINOPIPERIDIN-1-YL]-1,3-DIMETHYL-2,6-DIOXO-1,2,3,6-TETRAHYDRO-7H-PURIN-7-YL}METHYL)BENZONITRILE
- Linagliptin
|
Diseases |
|
|
GWAS |
|
|
Protein-Protein Interactions |
32 interactors:
ADRBK2
ARRB2
ATP13A2
CCR5
CD4
CTSG
CXCL12
DPP4
ELANE
GNA13
GNAI1
HLA-C
HSPA8
ITCH
JAK1
JAK2
JAK3
MYBL2
MYH9
PTK2
PTPN11
PTPN6
PTPRC
SDC4
SOCS1
SOCS3
STAT1
STAT2
STAT3
STAT5B
USP14
VAV1
|
16 interactors:
ADA
CCL11
CCL22
CCL3L1
CCL5
CD4
CPAMD8
CXCL10
CXCL11
CXCL12
CXCL9
CXCR4
DKK1
FAP
GRP
PTPRC
|
Entrez ID |
7852 |
1803 |
HPRD ID |
01217 |
02187 |
Ensembl ID |
ENSG00000121966
|
ENSG00000197635
|
Uniprot IDs |
P61073
|
P27487
|
PDB IDs |
2K03
2K04
2K05
3ODU
3OE0
3OE6
3OE8
3OE9
|
1J2E
1N1M
1NU6
1NU8
1PFQ
1R9M
1R9N
1RWQ
1TK3
1TKR
1U8E
1W1I
1WCY
1X70
2AJL
2BGN
2BGR
2BUB
2FJP
2G5P
2G5T
2G63
2HHA
2I03
2I78
2IIT
2IIV
2JID
2OAG
2OGZ
2OLE
2ONC
2OPH
2OQI
2OQV
2P8S
2QJR
2QKY
2QOE
2QT9
2QTB
2RGU
2RIP
3BJM
3C43
3C45
3CCB
3CCC
3D4L
3EIO
3F8S
3G0B
3G0C
3G0D
3G0G
3H0C
3HAB
3HAC
3KWF
3KWJ
3NOX
3O95
3O9V
3OC0
3OPM
3Q0T
3Q8W
3QBJ
3SWW
3SX4
3VJK
3VJL
3VJM
3W2T
4A5S
4DSA
4DSZ
4DTC
4G1F
4JH0
4KR0
4L72
4LKO
|
Enriched GO Terms of Interacting Partners? |
|
|
Tagcloud ? |
capture
ccr1
ccr2
ccr5
ccr7
cd40
chemokine
chemokines
cxcr1
dc
dendritic
ebi1
elc
immature
inflamed
insight
lost
lymphoid
marginally
maturation
mature
maturing
migrate
nodes
organs
phases
respective
responded
responsiveness
|
albuminuria
ameliorate
bioavailability
capability
dipeptidyl
english
experimentally
glp
indirectly
insufficient
interfere
journals
language
march
microalbuminuria
microangiopathy
microvascular
modifying
nephropathy
neuropathy
nonincretin
peer
peptidase
preliminary
retinopathy
retrieved
scanned
ulcer
|
Tagcloud (Difference) ? |
capture
ccr1
ccr2
ccr5
ccr7
cd40
chemokine
chemokines
cxcr1
dc
dendritic
ebi1
elc
immature
inflamed
insight
lost
lymphoid
marginally
maturation
mature
maturing
migrate
nodes
organs
phases
respective
responded
responsiveness
|
albuminuria
ameliorate
bioavailability
capability
dipeptidyl
english
experimentally
glp
indirectly
insufficient
interfere
journals
language
march
microalbuminuria
microangiopathy
microvascular
modifying
nephropathy
neuropathy
nonincretin
peer
peptidase
preliminary
retinopathy
retrieved
scanned
ulcer
|
Tagcloud (Intersection) ? |
|